All In Biotech

Drug Trial Radar · NCT00841126

Phase III Study to Investigate the Safety and Efficacy of Fermagate and Lanthanum Carbonate

An Open, Randomized, Controlled, Parallel Group, Phase III Study to Investigate the Safety and Efficacy of Fermagate and Lanthanum Carbonate Together With a Randomized Placebo Controlled Double Blind Fermagate Comparison in Hemodialysis Patients With Hyperphosphatemia

Last checked: Nov 20, 2026Latest source record: Oct 19, 2010 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedPivotal-lookingPhase 3. Randomized with 657 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

657

Planned (sponsor's estimate)

Start

Jul 2009

Primary completion

Jul 2011

Study completion Jul 2011

Sponsor

Lead sponsor
Ineos Healthcare LimitedIndustry
Sponsor type
Industry
First posted
Feb 11, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Magnesium iron hydroxycarbonate is a phosphate binder that absorbs phosphate from food, reducing the amount that the body can absorb. The purpose of this study is to assess the efficacy of magnesium iron hydroxycarbonate in subjects requiring hemodialysis, compared with a marketed phosphate binder, lanthanum carbonate and placebo.

Conditions

  • Chronic Kidney Failure

Interventions

  • Magnesium iron hydroxycarbonateDrug

    500 mg tablets, administered orally: initial dosage 500 or 1000 mg (total daily dose 1500 or 3000 mg) depending on serum phosphate concentration, titrated to a maximum DAILY dose of 9000 mg). The total daily dose should be divided and taken with meals. Any SINGLE dose should not exceed 3000 mg.

  • Lanthanum carbonateDrug

    750 mg chewable tablets, administered orally: initial dosage 750 mg up to 3-times daily (total daily dose 2250 mg), titrated to a maximum SINGLE dose of 1500 mg (DAILY dose 3750 mg). The total daily dose should be divided and taken with meals.

  • PlaceboDrug

    0 mg (500 mg-size) tablets, administered orally: The total daily dose should be divided and taken with meals. Any SINGLE dose should not exceed 6 tablets.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Stage 1: Control or not the level of serum phosphateTime frame: Within the treatment period
  2. Stage 2: Change from treated baseline in mean serum phosphateTime frame: At 4 weeks

Locations

112 sites in 11 countries. Site status is shown where the registry gives one.

  • Nephrology Associates PC

    Birmingham, Alabama

  • Arizona Kidney Disease and Hypertension Center

    Phoenix, Arizona

  • Southwest Kidney Institute

    Tempe, Arizona

  • US Renal Care

    Jonesboro, Arkansas

  • Wright Steven (Private Practice)

    Pine Bluff, Arkansas

  • University of Southern California

    Los Angeles, California

  • Apex Research of Riverside

    Riverside, California

  • North America Research Institute

    San Dimas, California

  • Kidney Center Inc.

    Simi Valley, California

  • Nephrology Educational Services and Research

    Tarzana, California

  • American Institute of Research

    Whittier, California

  • North Valley Nephrology

    Yoba City, California

  • Western Nephrology & Metabolic Bone Disease PC

    Arvada, Colorado

  • Western Nephrology & Metabolic Bone Disease PC

    Westminister, Colorado

  • Nephrology and Hypertension Associates

    Middlebury, Connecticut

  • South Florida Nephrology Group P.A.

    Coral Springs, Florida

  • Outcomes Research International Inc.

    Hudson, Florida

  • Nephrology Associates of South Miami

    Miami, Florida

  • Nephrology Associates Research Center

    Panama City, Florida

  • Cleveland Clinic Florida

    Weston, Florida

  • Renal Physicians of Georgia PC

    Macon, Georgia

  • Boise Kidney & Hypertension Institute

    Meridian, Idaho

  • Research by Design LLC

    Evergreen Park, Illinois

  • North Suburban Nephrology

    Gurnee, Illinois

  • Kansas Nephrology Research Institute LLC

    Wichita, Kansas

  • Research Nurse Specialists LLC

    Lafayette, Louisiana

  • Lazowski Piotr MD- PC

    Plymouth, Massachusetts

  • Fallon Clinic - Winthrop

    Worcester, Massachusetts

  • William Beaumont Hospitals

    Berkley, Michigan

  • St. Clair Specialty Physicians PC

    Detroit, Michigan

  • Nephrology Associates P.C.

    Columbus, Mississippi

  • Creighton University

    Omaha, Nebraska

  • Kantor Nephrology Consultants Ltd.

    Las Vagas, Nevada

  • Brookdale Physicians Dialysis Associates

    Brooklyn, New York

  • Hypertension and Renal Research Group

    Buffalo, New York

  • Lower Manhattan Dialysis Center

    New York, New York

  • Long Island Hypertension and Nephrology PLLC

    Port Washington, New York

  • Wake Nephrology Associates PA

    Raleigh, North Carolina

  • University of Cincinnati Medical Center

    Cinncinnati, Ohio

  • MetroHealth Medical Center

    Cleveland, Ohio

Showing 40 of 112 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.